Stock Market Reviews

Read and share opinions on SLS (SELLAS Life Sciences Group, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Nov 12, 2025
• SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
  Nov 3, 2025
• Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase
  Oct 29, 2025
• SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
  Oct 27, 2025
• SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
  Oct 22, 2025
• SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
  Oct 13, 2025
• SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
  Sep 30, 2025
• SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
  Sep 11, 2025
• SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  Aug 12, 2025
• SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
  Aug 7, 2025
• SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
  Jul 31, 2025
• Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial
  Jul 15, 2025
• SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
  Jun 24, 2025
• SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
  Jun 5, 2025
• SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
  Jun 2, 2025
• SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
  May 20, 2025
• SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
  May 15, 2025